Stavudine (d4T)

Catalog No.S1398 Synonyms: BMY-27857, Sanilvudine, NSC 163661

For research use only.

Stavudine (d4T, BMY-27857, Sanilvudine, NSC 163661) is a nucleoside analog reverse transcriptase inhibitor (NARTI) active against HIV.

Stavudine (d4T) Chemical Structure

CAS No. 3056-17-5

Selleck's Stavudine (d4T) has been cited by 4 Publications

Purity & Quality Control

Choose Selective Reverse Transcriptase Inhibitors

Other Reverse Transcriptase Products

Biological Activity

Description Stavudine (d4T, BMY-27857, Sanilvudine, NSC 163661) is a nucleoside analog reverse transcriptase inhibitor (NARTI) active against HIV.
Targets
Reverse transcriptase [1]
In vitro

Stavudine alteres the lipid phenotype, decreasing the lipid content and expression of markers involved in lipid metabolism, namely C/EBPalpha, peroxisome proliferator-activated receptor gamma, adipocyte lipid binding protein 2, fatty acid synthase and acetyl-coenzyme A carboxylase. Stavudine drives 5-10% of 3T3-F442A cells towards apoptosis, and reduces the lipid content and survival of differentiated 3T3-L1 adipocytes. Stavudine increases mitochondrial mass by two to fourfold, and loweres the mitochondrial membrane potential (JC-1 stain). [1] stavudine inhibits p24 antigen production by HIV-I in PBMC with EDsos ranging from 0.04 μM to 0.2 μM. [2] Stavudine produces significant mitochondrial dysfunction with a 1.5-fold increase in cellular lactate to pyruvate ratios. Stavudine causes a dose-dependent decrease in mtDNA amplification and a correlative increase in abundance of markers of mitochondrial oxidative stress. Stavudine treatment elevates mitochondrial reactive oxygen species (ROS), enhances mitochondrial oxidative stress, and contributes mechanistically to NRTI-induced toxicity. [3]

In vivo Stavudine (500 mg/kg/day) results in lack of significant oxidative mtDNA lesions (as assessed by long polymerase chain reaction experiments), and normal blood lactate/pyruvate ratios in lean mice. Stavudine (500 mg/kg/day) can decrease hepatic and muscle mtDNA in lean mice and can also cause ketoacidosis during fasting without altering mtDNA. Stavudine (500 mg/kg/day) depletes WAT mtDNA only in obese mice. [4]

Protocol (from reference)

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
0.5% CMC Na
For best results, use promptly after mixing.

30mg/mL

Chemical Information

Molecular Weight 224.21
Formula

C10H12N2O4

CAS No. 3056-17-5
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1=CN(C(=O)NC1=O)C2C=CC(O2)CO

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01178684 Completed -- HIV South East Asia Research Collaboration with Hawaii|University of Hawaii May 2010 --
NCT00455585 Completed Drug: nevirapine stavudine lamivudine HIV Infections Makerere University|Department of Foreign Affairs Ireland January 2007 Phase 4
NCT00235222 Unknown status Drug: stavudine HIV Groupe Hospitalier Pitie-Salpetriere|Bristol-Myers Squibb June 2004 Phase 4
NCT00116116 Completed Drug: efavirenz stavudine extended release lamivudine HIV Infections|AIDS Bristol-Myers Squibb March 2002 Phase 4

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Stavudine (d4T) | Stavudine (d4T) supplier | purchase Stavudine (d4T) | Stavudine (d4T) cost | Stavudine (d4T) manufacturer | order Stavudine (d4T) | Stavudine (d4T) distributor